Mark Erlander - Net Worth and Insider Trading

Mark Erlander Net Worth

The estimated net worth of Mark Erlander is at least $66,099 dollars as of 2024-06-15. Mark Erlander is the CEO of Cardiff Oncology Inc and owns about 24,481 shares of Cardiff Oncology Inc (CRDF) stock worth over $66,099. Details can be seen in Mark Erlander's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Mark Erlander has not made any transactions after 2022-11-25 and currently still holds the listed stock(s).

Transaction Summary of Mark Erlander

To

Mark Erlander Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Mark Erlander owns 1 companies in total, including Cardiff Oncology Inc (CRDF) .

Click here to see the complete history of Mark Erlander’s form 4 insider trades.

Insider Ownership Summary of Mark Erlander

Ticker Comapny Transaction Date Type of Owner
CRDF Cardiff Oncology Inc 2022-11-25 Chief Scientific Officer

Mark Erlander Latest Holdings Summary

Mark Erlander currently owns a total of 1 stock. Mark Erlander owns 24,481 shares of Cardiff Oncology Inc (CRDF) as of November 25, 2022, with a value of $66,099.

Latest Holdings of Mark Erlander

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
CRDF Cardiff Oncology Inc 2022-11-25 24,481 2.70 66,099

Holding Weightings of Mark Erlander


Mark Erlander Form 4 Trading Tracker

According to the SEC Form 4 filings, Mark Erlander has made a total of 3 transactions in Cardiff Oncology Inc (CRDF) over the past 5 years, including 3 buys and 0 sells. The most-recent trade in Cardiff Oncology Inc is the acquisition of 10,000 shares on November 25, 2022, which cost Mark Erlander around $14,300.

Insider Trading History of Mark Erlander

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Mark Erlander Trading Performance

GuruFocus tracks the stock performance after each of Mark Erlander's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Mark Erlander is 69.07%. GuruFocus also compares Mark Erlander's trading performance to market benchmark return within the same time period. The performance of stocks bought by Mark Erlander within 3 months outperforms 2 times out of 4 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Mark Erlander's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Mark Erlander

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 4 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 16.34 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 13.84 LIMIT LIMIT LIMIT LIMIT LIMIT

Mark Erlander Ownership Network

Ownership Network List of Mark Erlander

No Data

Ownership Network Relation of Mark Erlander

Insider Network Chart

Mark Erlander Owned Company Details

What does Cardiff Oncology Inc do?

Who are the key executives at Cardiff Oncology Inc?

Mark Erlander is the Chief Scientific Officer of Cardiff Oncology Inc. Other key executives at Cardiff Oncology Inc include Chief Medical Officer Fairooz Kabbinavar , Chief Financial Officer James E. Levine , and Chief Scientific Officer Tod Smeal .

Cardiff Oncology Inc (CRDF) Insider Trades Summary

Over the past 18 months, Mark Erlander made no insider transaction in Cardiff Oncology Inc (CRDF). Other recent insider transactions involving Cardiff Oncology Inc (CRDF) include a net purchase of 52,950 shares made by Gary W Pace ,

In summary, during the past 3 months, insiders sold 0 shares of Cardiff Oncology Inc (CRDF) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cardiff Oncology Inc (CRDF) were sold and 52,950 shares were bought by its insiders, resulting in a net purchase of 52,950 shares.

Cardiff Oncology Inc (CRDF)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Cardiff Oncology Inc Insider Transactions

No Available Data

Mark Erlander Mailing Address

Above is the net worth, insider trading, and ownership report for Mark Erlander. You might contact Mark Erlander via mailing address: C/o Trovagene, Inc., 11055 Flintkote Avenue, Suite A, San Diego Ca 92121.

Discussions on Mark Erlander

No discussions yet.